DCM
ELDN icon

Discovery Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Discovery Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-94
Closed -$203K – 114
2015
Q2 		$203K Sell
94
-1,783
-95% -$3.45M ﹤0.01% 97
2015
Q1 		$3.44M Hold
1,877
– – 0.04% 86
2014
Q4 		$4.48M Hold
1,877
– – 0.05% 106
2014
Q3 		$4.6M Buy
+1,877
New +$5.33M 0.05% 84

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Discovery Capital Management's ELDN Position: Q3 2015 in Review

Discovery Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2015, closing a stake of 94 shares — an estimated $203K sold.

Discovery Capital Management first reported a position in ELDN in Q3 2014 and held it in 4 quarters. The position peaked at $4.6M in Q3 2014. 49 funds tracked by Wall St. Rank hold ELDN as of Q3 2015.

  • Discovery Capital Management reported no remaining Eledon Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Discovery Capital Management sold 94 Eledon Pharmaceuticals shares in Q3 2015, an estimated $203K.
  • Discovery Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Discovery Capital Management's Eledon Pharmaceuticals position peaked at $4.6M in Q3 2014.
  • 49 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2015.

Based on Discovery Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.